EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Qualification of a quantitative stability indicating potency assay for mRNA-LNP vaccine candidates

Anan Bzami, Marcus Estrada, Tim Schofield, Jessica A White

Gates Open Research · 2026

DOI: 10.12688/gatesopenres.16382.1 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Gates Open Research, 2026. Verfasst von Anan Bzami und 3 weiteren Autor:innen. Beteiligte Einrichtung: PATH, Seattle, WA, 8103,, USA. Hauptthemen laut MEDLINE: COVID-19 Vaccines, SARS-CoV-2, Vaccine Potency, COVID-19. Die Arbeit nennt 18 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Institute for Innovation in Manufacturing Biopharmaceuticals, Gates Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Potency assays assess the functional integrity of a target antigen to ensure that the final drug product is consistent between the commercial and clinical trial lots. Existing mRNA-LNP vaccine potency assays require complex quantification methods, such as flow cytometry, which are not widely adaptable to routine use by low- and middle-income country (LMIC) manufacturers or National Regulatory Agency (NRA) laboratories. To address the need for more accessible mRNA-LNP vaccine potency methods, an enzyme-linked immunosorbent assay (ELISA) was developed to quantify the target proteins produced by an mRNA-LNP vaccine after cell transfection. SARS-CoV-2 mRNA-LNP targeting the wild-type (Wuhan) strain was used as a model vaccine for the development and qualification of an ELISA method. The adaptability of the ELISA to other mRNA-LNP vaccines was demonstrated by altering the method used for quantification of a commercial Omicron mRNA-LNP vaccine. Alternative mRNA-LNP potency methods, such as western blotting, fluorescence focus assay (FFA), and direct ELISA were used as analogous methods for comparison. The developed quantitative stability-indicating ELISA is a globally accessible potency method that utilizes existing equipment and knowledge. Testing conducted on wild type SARS CoV-2 and Omicron vaccines demonstrates the adaptability of the method to other mRNA vaccine targets.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

COVID-19 VaccinesSARS-CoV-2Vaccine PotencyCOVID-19Enzyme-Linked Immunosorbent AssayHumansRNA, MessengerAnimalsVaccines, Synthetic

Stichwörter der Autor:innen

ELISAPotencymRNA-LNP

Substanzen

COVID-19 VaccinesRNA, MessengerVaccines, Synthetic

Autor:innen und Institutionen

  • PATH, Seattle, WA, 8103,, USA.
  • CMC Science, Germantown,, MD, 20876, USA.

Förderung

  • National Institute for Innovation in Manufacturing Biopharmaceuticals
  • Gates Foundation

Zitieren

APA

Bzami, A., Estrada, M., Schofield, T., & White, J. A. (2026). Qualification of a quantitative stability indicating potency assay for mRNA-LNP vaccine candidates. Gates Open Research. https://doi.org/10.12688/gatesopenres.16382.1

Vancouver

Bzami A, Estrada M, Schofield T, White JA. Qualification of a quantitative stability indicating potency assay for mRNA-LNP vaccine candidates. Gates Open Research. 2026. doi:10.12688/gatesopenres.16382.1

BibTeX
@article{Bzami2026,
  author = {Bzami, Anan and Estrada, Marcus and Schofield, Tim and White, Jessica A},
  title = {Qualification of a quantitative stability indicating potency assay for mRNA-LNP vaccine candidates},
  journal = {Gates Open Research},
  year = {2026},
  doi = {10.12688/gatesopenres.16382.1}
}
Kostenlos starten →